Key result
Real-world ASCVD registry reveals substantial non-achievement rates for 2022 JAS guideline LDL-C goals.
Observational
Yes
This study evaluates the real-world non-achievement rates of the stringent LDL-C targets introduced in the 2022 Japan Atherosclerosis Society Guidelines among ASCVD patients.
Background: Low-density lipoprotein cholesterol (LDL-C) is an established therapeutic target for atherosclerotic cardiovascular diseases (ASCVD), particularly in high-risk individuals. In 2022, the Japan Atherosclerosis Society Guidelines (JAS-GL) for Prevention of Atherosclerotic Cardiovascular Diseases introduced more stringent LDL-C targets to reduce ASCVD. We evaluated the non-achievement rates of the LDL-C goals across risk groups using a nationwide real-world dataset, which included a broad range of ASCVD patients.
No takes yet. Share an insight, caveat, or question.
Tsukamoto et al. (2026) conducted an observational in Atherosclerotic cardiovascular diseases (ASCVD). LDL-C goal achievement was evaluated on Non-achievement rates of LDL-C goals. The non-achievement rates of the 2022 Japan Atherosclerosis Society Guidelines LDL-C goals were evaluated across risk groups in a nationwide real-world dataset of ASCVD patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: